Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
Statistics in Medicine|February 16, 2006
Conditional power calculations for clinical trials with historical controlsEdward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Monitoring for lack of benefit: a critical component of a randomized clinical trialBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|April 4, 2009
Stopping clinical trials early for benefit: impact on estimationBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2018
Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment EffectEdward L Korn, Boris Freidlin
Biometrics|September 29, 2007
A note on controlling the number of false positivesEdward L Korn, Boris Freidlin
Nature Reviews. Clinical Oncology|November 28, 2013
Biomarker enrichment strategies: matching trial design to biomarker credentialsBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|August 11, 2017
Sample size adjustment designs with time-to-event outcomes: A cautionBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Transparency in interim monitoringBoris Freidlin, Edward L Korn
JCO Oncology Practice|July 10, 2024
Two-to-One Randomization: Rarely AdvisableBoris Freidlin, Edward L Korn
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
The cross-validated adaptive signature designBoris Freidlin, Wenyu Jiang, Richard Simon
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
Statistics in Medicine|February 16, 2006
Conditional power calculations for clinical trials with historical controlsEdward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Monitoring for lack of benefit: a critical component of a randomized clinical trialBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|April 4, 2009
Stopping clinical trials early for benefit: impact on estimationBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2018
Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment EffectEdward L Korn, Boris Freidlin
Biometrics|September 29, 2007
A note on controlling the number of false positivesEdward L Korn, Boris Freidlin
Nature Reviews. Clinical Oncology|November 28, 2013
Biomarker enrichment strategies: matching trial design to biomarker credentialsBoris Freidlin, Edward L Korn
Clinical Trials (London, England)|August 11, 2017
Sample size adjustment designs with time-to-event outcomes: A cautionBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Transparency in interim monitoringBoris Freidlin, Edward L Korn
JCO Oncology Practice|July 10, 2024
Two-to-One Randomization: Rarely AdvisableBoris Freidlin, Edward L Korn
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
The cross-validated adaptive signature designBoris Freidlin, Wenyu Jiang, Richard Simon
Pageof 12